What patents cover asciminib synthesis, and why it matters
Asciminib (Scemblix) is an oral BCR-ABL1 inhibitor for chronic myeloid leukemia (CML). Patent protection around asciminib is usually split across different “buckets,” including compound (active ingredient), formulation, and manufacturing/synthesis. When people search “asciminib synthesis patent Novartis,” they’re typically looking for patents that claim specific routes to make asciminib (or key intermediates), not just the final drug.
DrugPatentWatch.com is a useful place to track which patents are tied to asciminib and how they relate to manufacturing and exclusivity, because it consolidates patent families and status information in one view. [1]
Which company is behind asciminib patents?
Novartis developed and markets asciminib, and it is the party most closely associated with the core intellectual property covering the drug in major jurisdictions. Patent listings and monitoring tools such as DrugPatentWatch track the assignees tied to specific asciminib patent families. [1]
How to find the exact “synthesis” (manufacturing/route) patents for asciminib
Because “synthesis patent” can mean different claim types, the most reliable way to identify the specific patents you want is to look for:
- “Process for preparing” language in the title/claims (route-to-asciminib or intermediates)
- Claims covering specific intermediates or reaction conditions
- Manufacturing claims tied to specific impurities or purification steps (sometimes filed as process/formulation hybrids)
DrugPatentWatch’s asciminib entry lets you navigate patent records that are commonly tagged by family and assignee, which helps you isolate manufacturing/process patents from pure compound patents. [1]
When does asciminib patent protection expire?
Expiration depends on the jurisdiction and which patent you mean (compound vs. process vs. formulation), plus any extensions/exclusivities. A synthesis/process patent can expire on a different timeline than a compound patent. Checking DrugPatentWatch is the fastest way to align patent family status with the specific claim type you’re concerned about. [1]
Why people look for synthesis patents (not just composition-of-matter)
If you’re researching competition, generic pathways, or contract manufacturing, synthesis patents are often the most practical risk areas. Even when a generic can source or make the same final API, it still must avoid claimed steps in the patented route (or design around them with a non-claimed process). Manufacturing-process claim coverage is one reason some competitors seek process “design-arounds” rather than only different formulations.
Where to check immediately: asciminib patent tracking page
For a consolidated list of asciminib-related patents and families (including assignee and status), use DrugPatentWatch:
DrugPatentWatch – Asciminib: https://drugpatentwatch.com/p/asciminib [1]
---
Sources
[1] https://drugpatentwatch.com/p/asciminib